Aarti Drugs Ltd
NSE:AARTIDRUGS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aarti Drugs Ltd
NSE:AARTIDRUGS
|
IN |
Aarti Drugs Ltd
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,450 full-time employees. The Company, through its wholly-owned subsidiary Pinnacle Life Science Private Limited, is focused on producing formulations. The Company’s products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole and Ofloxacin. Its pharma intermediates products are Tinidazole, Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide and Raloxifene. The company also offers specialty chemicals, such as Benzene Sulphonyl Chloride and Methyl Nicotinate. The Company’s products under development include Alcoholism Treatment, Anticoagulant, Antihyperphosphatemia, Anti-cholestrol, Cardiovascular, Cardiprotectant and Antidiabetic.
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,450 full-time employees. The Company, through its wholly-owned subsidiary Pinnacle Life Science Private Limited, is focused on producing formulations. The Company’s products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole and Ofloxacin. Its pharma intermediates products are Tinidazole, Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide and Raloxifene. The company also offers specialty chemicals, such as Benzene Sulphonyl Chloride and Methyl Nicotinate. The Company’s products under development include Alcoholism Treatment, Anticoagulant, Antihyperphosphatemia, Anti-cholestrol, Cardiovascular, Cardiprotectant and Antidiabetic.
Revenue Growth: Aarti Drugs reported Q3 FY '26 revenue of INR 602.9 crores, up 8% year-on-year, with 9M revenue also rising 8%.
Profit Recovery: Q3 PAT increased 58% YoY to INR 40.5 crores, while EBITDA margin fell to 9.3% due to lower utilization and cost pressures.
Operational Challenges: The quarter was impacted by weaker antibiotic demand, supply chain delays from China, a voluntary plant shutdown, and underutilization at new facilities.
Positive Outlook: Management sees Q3 as an inflection point, with January sales improving and expectations for stronger quarters ahead as new plants ramp up.
CapEx Plans: Ongoing investments of INR 150–200 crores per year are planned for the next two years, with significant spending on oncology and capacity expansions.
Margin Recovery Expected: EBITDA margins are targeted to recover to 12–13% in the near term, and eventually to 14–15% as new projects stabilize.
